Dane C. Andreeff net worth and biography

Dane Andreeff Biography and Net Worth

Mr. Andreeff is the General Partner and Portfolio Manager of Maple Leaf Partners, L.P. and the President of Andreeff Equity Advisors, L.L.C. Mr. Andreeff has managed investment portfolios since 1996 for Andreeff Equity, L.P., Andreeff Overseas Ltd. and Clover Partners, LP. Prior to managing portfolios, Mr. Andreeff worked as an associate analyst at Furman Selz and Granite Capital International Group. Currently, Mr. Andreeff serves as a Director of TraceSecurity Inc., HDL Therapeutics, Inc. and Myocardial Solutions, Ltd.

Mr. Andreeff received his Master's degree in Economics from the University of Texas at Arlington in 1991 and Bachelor's degree in Economics from the University of Texas at Arlington in 1989.

What is Dane C. Andreeff's net worth?

The estimated net worth of Dane C. Andreeff is at least $119,938.88 as of December 16th, 2022. Mr. Andreeff owns 332,517 shares of Helius Medical Technologies stock worth more than $119,939 as of February 5th. This net worth estimate does not reflect any other assets that Mr. Andreeff may own. Learn More about Dane C. Andreeff's net worth.

How do I contact Dane C. Andreeff?

The corporate mailing address for Mr. Andreeff and other Helius Medical Technologies executives is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. Helius Medical Technologies can also be reached via phone at (215) 944-6100 and via email at [email protected] Learn More on Dane C. Andreeff's contact information.

Has Dane C. Andreeff been buying or selling shares of Helius Medical Technologies?

Dane C. Andreeff has not been actively trading shares of Helius Medical Technologies during the last quarter. Most recently, on Friday, December 16th, Dane Andreeff bought 80,041 shares of Helius Medical Technologies stock. The stock was acquired at an average cost of $0.25 per share, with a total value of $20,010.25. Following the completion of the transaction, the chief executive officer now directly owns 332,517 shares of the company's stock, valued at $83,129.25. Learn More on Dane C. Andreeff's trading history.

Who are Helius Medical Technologies' active insiders?

Helius Medical Technologies' insider roster includes Dane Andreeff (CEO), and Jeffrey Mathiesen (CFO). Learn More on Helius Medical Technologies' active insiders.

Are insiders buying or selling shares of Helius Medical Technologies?

In the last twelve months, Helius Medical Technologies insiders bought shares 4 times. They purchased a total of 124,109 shares worth more than $43,978.97. The most recent insider tranaction occured on December, 16th when CEO Dane Andreeff bought 80,041 shares worth more than $20,010.25. Insiders at Helius Medical Technologies own 11.2% of the company. Learn More about insider trades at Helius Medical Technologies.

Information on this page was last updated on 12/16/2022.

Dane C. Andreeff Insider Trading History at Helius Medical Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2022Buy80,041$0.25$20,010.25332,517View SEC Filing Icon  
11/22/2022Buy10,000$0.28$2,800.00218,572View SEC Filing Icon  
9/12/2022Buy8,868$0.54$4,788.72144,819View SEC Filing Icon  
8/24/2022Buy25,200$0.65$16,380.0099,985View SEC Filing Icon  
12/17/2021Buy5,100$5.25$26,775.00View SEC Filing Icon  
11/12/2021Buy37,500$8.00$300,000.00View SEC Filing Icon  
6/27/2018Buy10,000$10.10$101,000.00View SEC Filing Icon  
12/22/2017Buy255,101$1.96$499,997.96View SEC Filing Icon  
11/13/2017Buy167,000$2.58$430,860.00View SEC Filing Icon  
See Full Table

Dane C. Andreeff Buying and Selling Activity at Helius Medical Technologies

This chart shows Dane Andreeff's buying and selling at Helius Medical Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Helius Medical Technologies Company Overview

Helius Medical Technologies logo
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.
Read More

Today's Range

Now: $0.36
Low: $0.35
High: $0.38

50 Day Range

MA: $0.31
Low: $0.22
High: $0.41

2 Week Range

Now: $0.36
Low: $0.20
High: $4.76


355,342 shs

Average Volume

852,023 shs

Market Capitalization

$10.17 million

P/E Ratio


Dividend Yield